BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 09, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/6 cls
Endo (NASDAQ:ENDP) Roth Capital Partners Scott Henry Price target Hold -10% $17.11
Henry lowered his target to $24 from $28. He said the company's pipeline strategy is not clear, adding that the pipeline has been decimated and relies heavily on Endo's acquisition of Indevus and recent in-licensing deals. Henry said he remains "skeptical on these deals."
Flamel (NASDAQ:FLML) Ladenburg Thalmann Matthew Kaplan Price target Buy 4% $4.76
Kaplan lowered his target to $13 from $15 after Flamel reported 4Q08 revenues of $9.5M, which missed his estimate by $3.3M. He also lowered his FY09 revenue estimate to $42.5M from $63.2M. He believes there is a low probability of the company finding partners for FT-105, a long-acting basal insulin in Phase I trials for diabetes, and IFN-alpha XL, a long-acting native interferon alpha-2b in Phase I/II for HCV.
Genentech (NYSE:DNA) Rodman Christopher James...

Read the full 1019 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >